3 November 2020 - Cost effectiveness analysis is an important tool for informing treatment coverage and pricing decisions, yet no consensus exists about what threshold for the incremental cost effectiveness ratio in dollars per quality-adjusted life-year gained indicates whether treatments are likely to be cost effective in the US.
This paper presents estimates of a U.S. cost effectiveness threshold based on health opportunity costs.